These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 25159877)

  • 1. Down syndrome-associated haematopoiesis abnormalities created by chromosome transfer and genome editing technologies.
    Kazuki Y; Yakura Y; Abe S; Osaki M; Kajitani N; Kazuki K; Takehara S; Honma K; Suemori H; Yamazaki S; Sakuma T; Toki T; Shimizu R; Nakauchi H; Yamamoto T; Oshimura M
    Sci Rep; 2014 Aug; 4():6136. PubMed ID: 25159877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pluripotent stem cell model of early hematopoiesis in Down syndrome reveals quantitative effects of short-form GATA1 protein on lineage specification.
    Matsuo S; Nishinaka-Arai Y; Kazuki Y; Oshimura M; Nakahata T; Niwa A; Saito MK
    PLoS One; 2021; 16(3):e0247595. PubMed ID: 33780474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of
    Barwe SP; Sebastian A; Sidhu I; Kolb EA; Gopalakrishnapillai A
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic roles of DYRK1A and GATA1 in trisomy 21 megakaryopoiesis.
    Sit YT; Takasaki K; An HH; Xiao Y; Hurtz C; Gearhart PA; Zhang Z; Gadue P; French DL; Chou ST
    JCI Insight; 2023 Oct; 8(23):. PubMed ID: 37906251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perturbed hematopoiesis in the Tc1 mouse model of Down syndrome.
    Alford KA; Slender A; Vanes L; Li Z; Fisher EM; Nizetic D; Orkin SH; Roberts I; Tybulewicz VL
    Blood; 2010 Apr; 115(14):2928-37. PubMed ID: 20154221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient abnormal myelopoiesis of a newborn not associated with chromosome 21 abnormalities or GATA1 mutations.
    Nakashima MO; Shetty S; Chicka M; Flagg A; Eng C; Cotta CV
    Pediatr Blood Cancer; 2015 Feb; 62(2):353-355. PubMed ID: 25175265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the understanding of transient abnormal myelopoiesis in Down syndrome.
    Watanabe K
    Pediatr Int; 2019 Mar; 61(3):222-229. PubMed ID: 30593694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell transcriptomics reveal individual and synergistic effects of Trisomy 21 and GATA1s on hematopoiesis.
    Takasaki K; Wafula EK; Kumar SS; Smith D; Sit YT; Gagne AL; French DL; Thom CS; Chou ST
    bioRxiv; 2024 Oct; ():. PubMed ID: 38826323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic Gata1 causes stage-specific megakaryocyte differentiation delay.
    Juban G; Sakakini N; Chagraoui H; Cruz Hernandez D; Cheng Q; Soady K; Stoilova B; Garnett C; Waithe D; Otto G; Doondeea J; Usukhbayar B; Karkoulia E; Alexiou M; Strouboulis J; Morrissey E; Roberts I; Porcher C; Vyas P
    Haematologica; 2021 Apr; 106(4):1106-1119. PubMed ID: 32527952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GATA1 in Normal and Pathologic Megakaryopoiesis and Platelet Development.
    Takasaki K; Chou ST
    Adv Exp Med Biol; 2024; 1459():261-287. PubMed ID: 39017848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The GATA1s isoform is normally down-regulated during terminal haematopoietic differentiation and over-expression leads to failure to repress MYB, CCND2 and SKI during erythroid differentiation of K562 cells.
    Halsey C; Docherty M; McNeill M; Gilchrist D; Le Brocq M; Gibson B; Graham G
    J Hematol Oncol; 2012 Aug; 5():45. PubMed ID: 22853316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Cellular Disease Models Reveal Synergistic Interaction of Trisomy 21 and GATA1 Mutations in Hematopoietic Abnormalities.
    Banno K; Omori S; Hirata K; Nawa N; Nakagawa N; Nishimura K; Ohtaka M; Nakanishi M; Sakuma T; Yamamoto T; Toki T; Ito E; Yamamoto T; Kokubu C; Takeda J; Taniguchi H; Arahori H; Wada K; Kitabatake Y; Ozono K
    Cell Rep; 2016 May; 15(6):1228-41. PubMed ID: 27134169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naturally occurring oncogenic GATA1 mutants with internal deletions in transient abnormal myelopoiesis in Down syndrome.
    Toki T; Kanezaki R; Kobayashi E; Kaneko H; Suzuki M; Wang R; Terui K; Kanegane H; Maeda M; Endo M; Mizuochi T; Adachi S; Hayashi Y; Yamamoto M; Shimizu R; Ito E
    Blood; 2013 Apr; 121(16):3181-4. PubMed ID: 23440243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stepwise GATA1 and SMC3 mutations alter megakaryocyte differentiation in a Down syndrome leukemia model.
    Arkoun B; Robert E; Boudia F; Mazzi S; Dufour V; Siret A; Mammasse Y; Aid Z; Vieira M; Imanci A; Aglave M; Cambot M; Petermann R; Souquere S; Rameau P; Catelain C; Diot R; Tachdjian G; Hermine O; Droin N; Debili N; Plo I; Malinge S; Soler E; Raslova H; Mercher T; Vainchenker W
    J Clin Invest; 2022 Jul; 132(14):. PubMed ID: 35587378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome.
    Garnett C; Cruz Hernandez D; Vyas P
    IUBMB Life; 2020 Jan; 72(1):119-130. PubMed ID: 31769932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct GATA1 Point Mutations in Monozygotic Twins With Down Syndrome and Transient Abnormal Myelopoiesis From a Triplet Pregnancy: A Case Report and Review of Literature.
    Yin L; Lovell MA; Wilson ML; Wei Q; Liang X
    Am J Clin Pathol; 2016 Dec; 146(6):753-759. PubMed ID: 28028114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia.
    Kanezaki R; Toki T; Terui K; Xu G; Wang R; Shimada A; Hama A; Kanegane H; Kawakami K; Endo M; Hasegawa D; Kogawa K; Adachi S; Ikeda Y; Iwamoto S; Taga T; Kosaka Y; Kojima S; Hayashi Y; Ito E
    Blood; 2010 Nov; 116(22):4631-8. PubMed ID: 20729467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete blood count differences in a cohort of Down syndrome neonates with transient abnormal myelopoiesis screened for GATA1 pathogenic variants.
    Orozco-Vela M; Corona-Rivera A; Cruz-Osorio RM; Mendoza-Maldonado L; Márquez-Mora A; Barba-Barba CC; Peña-Padilla C; Baldomero-López A; Bobadilla-Morales L; Corona-Rivera JR
    Am J Med Genet A; 2020 Sep; 182(9):2085-2093. PubMed ID: 32681702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia.
    Klusmann JH; Li Z; Böhmer K; Maroz A; Koch ML; Emmrich S; Godinho FJ; Orkin SH; Reinhardt D
    Genes Dev; 2010 Mar; 24(5):478-90. PubMed ID: 20194440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pluripotent stem cells reveal erythroid-specific activities of the GATA1 N-terminus.
    Byrska-Bishop M; VanDorn D; Campbell AE; Betensky M; Arca PR; Yao Y; Gadue P; Costa FF; Nemiroff RL; Blobel GA; French DL; Hardison RC; Weiss MJ; Chou ST
    J Clin Invest; 2015 Mar; 125(3):993-1005. PubMed ID: 25621499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.